Curated News
By: NewsRamp Editorial Staff
August 31, 2026

Oragenics Advances mTBI Drug, Tackles Listing Compliance

Discuss on LinkedInDiscuss on X, formerly TwitterDiscuss on SubstackDiscuss on TelegramParticipate in discussion on BlueskyParticipate in discussion on MastodonView history of this news story on GitHub
Original Source

TLDR

  • Oragenics advances ONP-002 in Phase IIa, aiming for FDA IND by end of 2026, despite NYSE listing compliance plan.
  • Oragenics dosed nine participants across three Australian sites, received FDA feedback on Type B meeting, and plans IND submission by year-end.
  • Oragenics' intranasal therapy for mild traumatic brain injury could offer a new treatment option for concussion patients.
  • Oragenics also received an NYSE American deficiency letter but has time to regain compliance until 2028.

Impact - Why it Matters

This news matters because it highlights the progress of a potential first-in-class treatment for mild traumatic brain injury, a condition affecting millions worldwide with no specific FDA-approved therapy. Oragenics' intranasal delivery platform could offer a non-invasive, rapid-acting option that may improve outcomes for concussion patients, including athletes and military personnel. However, the NYSE American deficiency letter introduces financial risk, reminding investors of the challenges clinical-stage biotech companies face in balancing scientific advancement with financial stability. The outcome of the FDA review and the company's compliance plan will be critical for stakeholders.

Summary

Clinical-stage biopharmaceutical company Oragenics (NYSE American: OGEN) is advancing its lead candidate ONP-002, a potential first-in-class intranasal treatment for concussion and mild traumatic brain injury (mTBI). The company has dosed nine participants across three active Australian clinical sites—Alfred Health, Mackay, and Royal Adelaide Hospital—in its Phase IIa feasibility trial. Oragenics has also received responses from the U.S. Food and Drug Administration (FDA) regarding its Type B meeting request briefing package submitted in July 2026. The company is reviewing these responses and remains on track to submit an Investigational New Drug (IND) application by the end of 2026. This progress underscores the potential of Oragenics' proprietary intranasal delivery platform, which could extend to other neurological conditions such as Parkinson's disease, Alzheimer's disease, PTSD, and anxiety disorders.

In parallel, Oragenics disclosed receiving an NYSE American deficiency letter on Aug. 26, 2026, concerning stockholders' equity requirements under Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide. The company has 45 days to submit a plan to regain compliance and intends to do so promptly. If accepted, the plan would allow Oragenics to maintain its listing during a cure period, with a compliance deadline of Feb. 25, 2028. This development adds a layer of financial scrutiny as the company navigates its clinical and regulatory milestones.

Oragenics is a clinical-stage biotechnology company dedicated to developing brain-targeted therapeutics. Its intranasal delivery technology is a key differentiator, offering a non-invasive route to the brain that could revolutionize treatment for various neurological disorders. The company is also working on commencing clinical trials in Australia for ONP-002, with U.S. Phase 2b trials planned to follow. For more information, visit oragenics.com. The latest news and updates are available at https://nnw.fm/OGEN. The full press release can be viewed at https://nnw.fm/HZ5fb.

Source Statement

This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Oragenics Advances mTBI Drug, Tackles Listing Compliance

Blockchain registration record for this content